Application of timosaponin n in the preparation of drugs for preventing and treating pulmonary fibrosis

A technology of timosaponin and pulmonary fibrosis, which is applied in the field of medicine, can solve the problems such as the prevention and treatment of pulmonary fibrosis which is not seen with timosaponin N, achieve important social and economic benefits, improve body weight, and improve the effect of pulmonary fibrosis.

Active Publication Date: 2021-02-19
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the prevention and treatment of pulmonary fibrosis by genosaponin N

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of timosaponin n in the preparation of drugs for preventing and treating pulmonary fibrosis
  • Application of timosaponin n in the preparation of drugs for preventing and treating pulmonary fibrosis
  • Application of timosaponin n in the preparation of drugs for preventing and treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1: Preparation of total extract of Anemarrhena 90% ethanol and preparation and characterization of timosaponin N

[0030] Take 2.0kg of Anemarrhena medicinal material, reflux extraction with 20L 90% (v / v) ethanol for 3 times, reflux for 2 hours each time, filter, and combine the filtrates to obtain the total extract of Anemarrhena 90% ethanol, reclaim ethanol, and concentrate under reduced pressure to 5L, reserve a part of the concentrate for subsequent administration.

[0031] Add 15L of water to dilute the remaining concentrate to a volume concentration of 0.1g crude drug / mL, filter the solution, and the filtrate is ready for loading. Pack the pre-treated macroporous adsorption resin HP20 into a column (5L), and after standing to balance, the filtrate is loaded. After loading the sample, wash with 6 times column volume (6BV) of water to remove impurities, then use 6BV of 30% (v / v) ethanol to remove impurities, use 6BV of 50% (v / v) ethanol to elute, and finall...

Embodiment 2

[0033] Example 2: Pharmacodynamic study of timosaponin N against pulmonary fibrosis

[0034] 1. Purpose of the experiment

[0035]To investigate the effect of timosaponin N on the model of pulmonary fibrosis induced by bleomycin in rats

[0036] 2. Experimental materials

[0037] 2.1 Animals: SPF grade SD rats, male, weighing 200±20g, purchased from Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2018-0006.

[0038] 2.2 Main instruments: analytical balance, electronic balance, 2mL syringe, gavage needle, animal cage, water bath, ultraviolet spectrophotometer, microplate reader, etc.

[0039] 2.3 Main drugs and reagents: bleomycin (Nippon Kayaku Co., Ltd.), pirfenidone (Beijing Condini Pharmaceutical Co., Ltd.), hydroxyproline kit (Nanjing Jiancheng Bioengineering Research Institute), TGF- β and TNF-α kit (R&DSystems).

[0040] 3. Experimental method

[0041] 3.1 Establishment and administration of rat pulmonary fibrosis model

[0042] Raise SD r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of timosaponin N in the preparation of medicines for preventing and treating pulmonary fibrosis. In the embodiment of the present invention, timosaponin N can significantly improve the body weight and lung index of bleomycin pulmonary fibrosis model rats, and significantly reduce biochemical indicators closely related to pulmonary fibrosis such as hydroxyproline content in lung tissue , TGF‑β and TNF‑α levels in alveolar lavage fluid. In addition, the combination of timosaponin N and pirfenidone can further synergistically improve the above indicators related to pulmonary fibrosis. It can be seen that timosaponin N or timosaponin N combined with pirfenidone can effectively improve the degree of pulmonary fibrosis in pulmonary fibrosis model rats, and has the prospect of being developed into an anti-pulmonary fibrosis drug, which has important social and economic benefits .

Description

technical field [0001] The invention belongs to the field of medicine and relates to a new application of timosaponin N, in particular to the application of timosaponin N in the preparation of medicines for preventing and treating pulmonary fibrosis. Background technique [0002] Interstitial lung disease (ILD) is a disease spectrum composed of many heterogeneous diseases caused by alveolar wall as the main lesion. Pulmonary fibrosis is the ultimate manifestation of various interstitial lung diseases. Due to alveolar damage, repeated damage and repair of lung tissue, fibroblast proliferation and activation, and a large amount of extracellular matrix deposition, a large number of collagen fibers are eventually deposited in lung tissue. Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis, accounting for more than half of patients with pulmonary fibrosis, and it is also the fastest developing and deteriorating disease among various fibrosis disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P11/00
CPCA61K31/7048A61P11/00
Inventor 陈宏李全
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap